Humoral response and safety of the third booster dose of BNT162b2 mRNA COVID-19 vaccine in patients with multiple sclerosis treated with ocrelizumab or fingolimod.
BNT162b2 mRNA vaccine
Booster dose
COVID-19
Fingolimod
Ocrelizumab
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
07
06
2022
accepted:
15
07
2022
revised:
14
07
2022
pubmed:
26
7
2022
medline:
2
11
2022
entrez:
25
7
2022
Statut:
ppublish
Résumé
The assessment of the safety and the humoral response to a third booster dose of the BNT162b2 mRNA COVID-19 vaccine is relevant in patients with Multiple Sclerosis (pwMS) treated with Ocrelizumab (OCR) or Fingolimod (FNG). Serum samples were collected from Healthy controls (HCs) and pwMS treated with OCR or FNG at the following time-points: before the first of two vaccine doses (T0); 8 (T1), 16 (T2), 24 (T3) weeks after the first dose; within 8 weeks before (T0b) and after (T1b) the booster dose. IgG antibodies to SARS-CoV-2 trimeric spike protein (Anti-TSP IgG) were quantified and expressed as binding antibody units (BAU)/mL. 40 HCs, 28 pwMS on OCR and 19 on FNG were included. At T0b 12 (42.9%) pwMS on OCR and 6 (31.6%) on FNG were still positive while, at T1b 16 (57.14%) pwMS on OCR and 16 (84.2%) on FNG, passed the threshold of positivity. The increase of Anti-TSP IgG levels at T1b was higher for: (i) HCs with respect to OCR (p < 0.001) and FNG (p = 0.032) groups; (ii) pwMS on FNG compared with pwMS on OCR (p < 0.001). No socio-demographic, clinical or laboratory variables were able to predict the anti-TSP IgG increase between T0b and T1b. Neither clinical relapses nor severe adverse events were reported in pwMS after each dose of vaccine. The third booster dose of BNT162b2 mRNA vaccine to OCR- and FNG-treated pwMS revives the humoral response, independently of any clinical variable, and manifests a good safety and tolerability profile.
Sections du résumé
BACKGROUND
BACKGROUND
The assessment of the safety and the humoral response to a third booster dose of the BNT162b2 mRNA COVID-19 vaccine is relevant in patients with Multiple Sclerosis (pwMS) treated with Ocrelizumab (OCR) or Fingolimod (FNG).
METHODS
METHODS
Serum samples were collected from Healthy controls (HCs) and pwMS treated with OCR or FNG at the following time-points: before the first of two vaccine doses (T0); 8 (T1), 16 (T2), 24 (T3) weeks after the first dose; within 8 weeks before (T0b) and after (T1b) the booster dose. IgG antibodies to SARS-CoV-2 trimeric spike protein (Anti-TSP IgG) were quantified and expressed as binding antibody units (BAU)/mL.
RESULTS
RESULTS
40 HCs, 28 pwMS on OCR and 19 on FNG were included. At T0b 12 (42.9%) pwMS on OCR and 6 (31.6%) on FNG were still positive while, at T1b 16 (57.14%) pwMS on OCR and 16 (84.2%) on FNG, passed the threshold of positivity. The increase of Anti-TSP IgG levels at T1b was higher for: (i) HCs with respect to OCR (p < 0.001) and FNG (p = 0.032) groups; (ii) pwMS on FNG compared with pwMS on OCR (p < 0.001). No socio-demographic, clinical or laboratory variables were able to predict the anti-TSP IgG increase between T0b and T1b. Neither clinical relapses nor severe adverse events were reported in pwMS after each dose of vaccine.
CONCLUSIONS
CONCLUSIONS
The third booster dose of BNT162b2 mRNA vaccine to OCR- and FNG-treated pwMS revives the humoral response, independently of any clinical variable, and manifests a good safety and tolerability profile.
Identifiants
pubmed: 35879563
doi: 10.1007/s00415-022-11296-4
pii: 10.1007/s00415-022-11296-4
pmc: PMC9314242
doi:
Substances chimiques
Fingolimod Hydrochloride
G926EC510T
ocrelizumab
A10SJL62JY
BNT162 Vaccine
0
COVID-19 Vaccines
0
RNA, Messenger
0
Immunoglobulin G
0
Antibodies, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6185-6192Informations de copyright
© 2022. The Author(s).
Références
Ther Adv Neurol Disord. 2021 Aug 13;14:17562864211038111
pubmed: 34413902
J Neurol. 2022 May;269(5):2286-2292
pubmed: 35235002
Neurotherapeutics. 2021 Jan;18(1):364-377
pubmed: 33258072
Neurol Sci. 2022 May;43(5):2947-2949
pubmed: 35171373
Lancet. 2021 Apr 10;397(10282):1347-1348
pubmed: 33770519
J Neurol Neurosurg Psychiatry. 2022 Apr;93(4):448-450
pubmed: 34408003
N Engl J Med. 2021 Oct 7;385(15):1393-1400
pubmed: 34525275
Mult Scler Relat Disord. 2022 May;61:103776
pubmed: 35364386
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
JAMA Neurol. 2022 Mar 1;79(3):307-309
pubmed: 35072702
Ther Adv Neurol Disord. 2021 Apr 22;14:17562864211012835
pubmed: 34035836
Neurol Sci. 2021 Sep;42(9):3523-3526
pubmed: 34128150
N Engl J Med. 2021 Dec 9;385(24):e84
pubmed: 34614326
EBioMedicine. 2021 Oct;72:103581
pubmed: 34563483
Nat Med. 2021 Nov;27(11):1990-2001
pubmed: 34522051
Ann Neurol. 2022 Jan;91(1):89-100
pubmed: 34687063
J Neuroimmunol. 2021 Dec 15;361:577746
pubmed: 34655991
JAMA Neurol. 2021 Dec 1;78(12):1510-1514
pubmed: 34554197
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Clin Chem Lab Med. 2021 Mar 15;59(8):1463-1467
pubmed: 33711225
Mult Scler Relat Disord. 2022 Apr;60:103724
pubmed: 35272145
JAMA Neurol. 2022 Apr 01;79(4):399-404
pubmed: 35212717